THE TAPE
WST · Medical Instruments · $29.1B

West Pharmaceutical Services, Inc.

$417.80▲ +0.33%
Last close
Relative strength
90RS
of 99, against every stock▲ +5 on the month
Powering up
Front line
+4.6%
six months against Medical Instruments
52-week range
−4.7%
from the high
$223.83$438.27
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 30, revenue +9% on a year ago
Why it is on no screen

WST passes every check below but is not on a screen — the screens also require the base to be the most recent structure, which this one is not.

A base has formed4.0 weeks, from 295.90 to 330.88.
Long enough to count4.0 weeks against 3 needed.
Shallow enough10.6% deep against 35% allowed.
Close to its pivot+26.3% from the pivot; listed down to -20%.
Relative strengthRS 90 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$384.46
-8.0% · tested 6× · last 6 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

West Pharmaceutical Services, Inc. is not on any of the screens right now. Its relative strength rating is 90, and it sits in Medical Instruments.

Against its industry
Front lineAhead of its industry over one, three and six months, in an industry fully aligned and ahead of the S&P 500.
One month against its industry
+4.5%
Three months against its industry
+20.4%
Six months against its industry
+4.6%

Read against an equal-weighted index of Medical Instruments, which is +31.0% against the S&P 500 over six months Fully aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 10.3% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$3.4B
+8.7% year on year
Operating margin
23.0%
gross 37.6%
Net margin
18.8%
Free cash flow
$453.4M
1.6% of market cap
Price to sales
8.57×
Price to earnings
45.5×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 29
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$874.5M
+0.3% QoQ · +8.7% YoY
Gross margin
39.7%
+2.0 pts QoQ
Net income
$214.0M
Positive
Free cash flow
$150.4M
Cash generating

What the numbers say

  • Revenue +8.7% year over year, +0.3% on the quarter
  • Good: Gross margin 39.7%, +2.0 points on the quarter
  • Good: Profitable: net income $214M, operating margin 30.6%
  • Good: Cash generating: operating cash flow $190M, free cash flow $150M
  • Good: Share count -2.5% in a year: buying back
  • Good: Net cash $261M · cash $464M
Revenue by quarter
Free cash flow
Net income
shares -2.5% in a year · net cash $261.2M
Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 2 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 added, 1 trimmed, 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Reported resultsFiling · 2026-10-30
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
New 52-week highTape · 2026-10-30
3.2x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-10-30
above 20d & 50d on 3.2x volume at 416.67
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
Unusual volumeTape · 2026-10-30
5.9 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Earnings comingEvent · 2026-10-28
reports 2026-10-29 bmo
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Red flag in a filingFiling · 2026-10-27
non-reliance
No measurable effect: stocks behave like random ones over the next three sessions (1,160 cases over 54 nights).
Earnings date movedEvent · 2026-10-15
2026-10-21 -> 2026-10-29
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
Unusual volumeTape · 2026-09-19
6.3 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
6
$5,443,749 total

Sold: Favorite Annette F.

Not counted above: 10 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-09-15 Favorite Annette F · Sr. VP & Chief HR Officeroption exercise2,524$226,251
2026-09-15 Favorite Annette F · Sr. VP & Chief HR Officersell2,524$921,260
2026-09-14 Favorite Annette F · Sr. VP & Chief HR Officeroption exercise2,500$224,100
2026-09-14 Favorite Annette F · Sr. VP & Chief HR Officersell2,500$887,500
2026-09-11 Favorite Annette F · Sr. VP & Chief HR Officeroption exercise2,500$224,100
2026-09-11 Favorite Annette F · Sr. VP & Chief HR Officersell2,500$862,500
2026-09-08 Favorite Annette F · Sr. VP & Chief HR Officeroption exercise2,817$235,135
2026-09-08 Favorite Annette F · Sr. VP & Chief HR Officersell2,817$960,062

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy3
Buy12
Hold0
Sell0
Strong sell1

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
West Pharmaceutical Services, Inc. (WST) — The Tape